Cargando…
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
Lurbinectedin is responsible for DNA recognition and binding, producing double-strand DNA (dsDNA) breaks thus resulting in apoptosis. Sensitivity to lurbinectedin is linked to the nucleotide excision repair (NER) system. Furthermore, irinotecan, a topoisomerase I inhibitor, provokes dsDNA breaks tha...
Autores principales: | Cortesi, Laura, Venturelli, Marta, Barbieri, Elena, Baldessari, Cinzia, Bardasi, Camilla, Coccia, Emanuele, Baglio, Federica, Rimini, Margherita, Greco, Stefano, Napolitano, Martina, Pipitone, Stefania, Dominici, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771728/ https://www.ncbi.nlm.nih.gov/pubmed/35070248 http://dx.doi.org/10.1177/20406223211063023 |
Ejemplares similares
-
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023) -
Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board
por: Rovesti, Giulia, et al.
Publicado: (2021) -
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
por: Cortesi, L., et al.
Publicado: (2023) -
Lurbinectedin for small cell lung cancer
Publicado: (2021) -
Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)